Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530659 · ClinicalTrials.gov registry record · Phase 2
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
A Phase 2 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01530659 is a Phase 2 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT01530659, a Phase 2 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
Interventions
- PROCEDURE Sham
- DRUG NT-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01530659
The ClinicalTrials.gov registry entry for NCT01530659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT01530659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01530659 about?
NCT01530659 is a clinical study titled "Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa". This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
What is the current status of trial NCT01530659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-01. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT01530659?
The interventions under investigation include: Sham (PROCEDURE), NT-501 (DRUG).
Who is sponsoring clinical trial NCT01530659?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.